When a parkinson's disease patient starts to hallucinate

Practical Neurology

Volumn 8, Issue 4, 2008, Pages 238-241

  Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ARTICLE; DIFFUSE LEWY BODY DISEASE; HALLUCINATION; HUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; RISK FACTOR;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DOPAMINE AGONISTS; HALLUCINATIONS; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 49249085015     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2008.152579     Document Type: Article

References (5)

1. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000; 123:733-45.
2. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005;4:605-10.
3. Poewe W. Psychosis in Parkinson's Disease. Mov Disord 2003; 18(Suppl 6):S80-87.
4. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51:811-14.
5. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-907.